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Background:Apathy is an enduring and debilitating feature related to poor outcome in patients with ﬁrst-episode
psychosis (FEP). The biological underpinnings of apathy are unknown. We tested if FEP patients with persistent
apathy (PA) differed from FEP patients without persistent apathy (NPA) in speciﬁc brain structure measures in
the early phase of illness.
Methods: A total of 70 Norwegian FEP patients were recruited within 1 year of ﬁrst adequate treatment. They
were deﬁned as having PA (N = 18) or NPA (N = 52) based on Apathy Evaluation Scale score at baseline and
1 year later. MRI measures of cortical thickness and subcortical structure volumes were compared between the
PA and NPA groups.
Results: The PA group had signiﬁcantly thinner left orbitofrontal cortex and left anterior cingulate cortex. The
results remained signiﬁcant after controlling for depressive symptoms and antipsychotic medication.
Discussion: FEP patients with persistent apathy in the early phase of their illness show brain structural changes
compared to FEP patients without persistent apathy. The changes are conﬁned to regions associated with
motivation, occur early in the disease course and appear selectively in PA patients when both groups are
compared to healthy controls.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Apathy is a predictor of poor functioning in psychosis patients
(Evensen et al., 2012; Faerden et al., 2009, 2013; Fervaha et al., 2013;
Foussias et al., 2011; Kiang et al., 2003; Konstantakopoulos et al.,
2011). Together with anhedonia, apathy constitutes a subdomain
within the negative symptom construct in schizophrenia (Blanchard
and Cohen, 2006).
Negative symptoms that persist are associated with poor functional
outcome andmay have distinct underlying neuropathology (Hovington
and Lepage, 2012). Antipsychotic treatment has only a limited effect on
negative symptoms. Investigating the different components of the
negative symptom construct, such as apathy, is important for develop-
ing better treatment (Kirkpatrick et al., 2006). The Apathy Evaluation
Scale (AES) offers a speciﬁc assessment of apathy (Marin et al., 1991).
In an overlapping sample, we found that apathy is a persistent featureric Research, Diakonhjemmet
l.: +47 22029900; fax: +47
L. Mørch-Johnsen).
. This is an open access article underin 30% of ﬁrst-episode psychosis (FEP) patients and related to poorer
general functioning (Faerden et al., 2010). The biological underpinning
of apathy in psychosis is unknown.
Numerous magnetic resonance imaging (MRI) studies have shown
structural brain differences in schizophrenia patients compared to
healthy controls both in cortical regions (Rimol et al., 2010; Bora et al.,
2011; Rimol et al., 2012), and subcortical structures (Haijma et al.,
2012; Shepherd et al., 2012). Knowledge on how structure abnormali-
ties relate to the symptoms of psychosis and clinical outcome in
patients with psychotic disorders is limited. Results from neuroimaging
studies focusing on persistent negative symptoms are inconsistent.
Frontotemporal volume reduction was found in patients with so-
called deﬁcit schizophrenia, i.e. enduring primary negative symptoms
for at least 12 months (Kirkpatrick et al., 1989), compared to patients
with non-deﬁcit schizophrenia (Galderisi et al., 2008; Cascella et al.,
2010; Fischer et al., 2012), although other studies have not found
differences in these regions (Buchanan et al., 1993; Turetsky et al.,
1995; Quarantelli et al., 2002; Voineskos et al., 2013). Most studies of
subcortical structures in deﬁcit schizophrenia have been negative
(Buchanan et al., 1993; Galderisi et al., 2008; Fischer et al., 2012;
Voineskos et al., 2013), but smaller volumes of putamen and substantiathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Lateral (left) and medial (right) view of the left hemisphere, showing the studied
orbitofrontal (red) and anterior cingulate (blue) cortical regions.
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volumes in frontal orbital gyrus and parahippocampal gyrus in FEP
patients with persistent negative symptoms, i.e. presence of negative
symptoms for 6 months in a stable period of psychosis (Buchanan,
2007) have been reported (Benoit et al., 2012). Inconsistencies in
ﬁndings could be due to variation of MR methods, use of different
regions of interest and underpowered samples.
Neither the deﬁnition of deﬁcit schizophrenia, nor the broader
deﬁnition of persistent negative symptoms considers the different
subdomains of the negative symptom construct. There is only one
published study of the relationship between brain structure and level
of apathy in psychosis patients. Roth et al. (2004), found smaller frontal
lobe volumes in chronic schizophrenia patients with high apathy levels
compared with low apathy patients.
In patients with Alzheimer's disease, apathy has been related to the
orbitofrontal cortex (OFC) and the anterior cingulate cortex (ACC)
(Guimaraes et al., 2008; Tunnard et al., 2011; Stanton et al., 2013). A
correlation between apathy and smaller gray matter volumes of the
caudate and putamen has also been reported (Bruen et al., 2008).
Apathy has been observed in patients with lesions in basal ganglia
(Bhatia and Marsden, 1994) and thalamus (Ghika-Schmid and
Bogousslavsky, 2000; Carrera and Bogousslavsky, 2006).
To search for brain structural markers of persistent apathy in
psychosis patients we tested if preselected brain regions differed
between FEP patients with persistent apathy (PA) compared to FEP
patients without persistent apathy (NPA). Measures of cortical
thickness and subcortical structure volumes were obtained by MRI
within a year after start of ﬁrst adequate treatment. First, based on
ﬁndings from studies of Alzheimer's disease (Guimaraes et al., 2008;
Tunnard et al., 2011; Stanton et al., 2013) and brain lesions (Bhatia
and Marsden, 1994; Ghika-Schmid and Bogousslavsky, 2000; Carrera
and Bogousslavsky, 2006), we hypothesized that the PA group shows
cortical thinning in OFC and ACC and reduced basal ganglia (caudate,
putamen, pallidum, and accumbens) and thalamus volumes. Second,
due to the limited number of studies on the topic, we explored group
differences in cortical thickness across the entire cortical surface, and
in all available subcortical structure volumes (hippocampus, amygdala,
ventricles, and cerebellum) that were not included in the hypothesis-
driven analyses.
2. Materials and methods
2.1. Subjects
Seventy patients participated in a longitudinal study on FEP with
1 year follow-up. Patients between ages 18 and 65 years were recruited
from psychiatric departments and outpatient clinics in Oslo between
2004 and 2007 as part of the Thematically Organized Psychosis (TOP)
Research study. A previous FEP study on apathy (Faerden et al., 2010)
included 65 of the patients in the current sample. Subjects were
considered FEP patients if antipsychotic naive or up to 52 weeks
after start of ﬁrst adequate treatment (hospitalization or receiving
antipsychotic medication for at least 12 weeks or until remission).
Exclusion criteria were: IQ b 70, a psychosis better accounted for by
substance abuse or somatic illness, a brain illness or a previous
moderate/severe head injury. All participants signed awritten informed
consent. The study was approved by the Regional Committee for
Medical Research Ethics and the Norwegian Data Inspectorate, and
conducted in accordance with the Helsinki declaration.
2.2. Clinical assessments
The clinical assessments, including a diagnostic evaluation using the
Structured Clinical Interview for DSM-IV axis I disorders (SCID-I)
modules A–E (First et al., 2002), were performed by trained psycholo-
gist or physicians at baseline and at 1 year follow-up. Apathy wasassessed using the clinical version of AES (AES-C) (Marin et al., 1991)
at both occasions. A shortened 12 item version (AES-C-Apathy) of the
original 18 items was used in the analyses as it has previously demon-
strated better psychometric properties than the full scale (Faerden
et al., 2008). Patients were deﬁned as having PA if they at both time
points had a score ≥27 on the AES-C-Apathy. This cut-off value is two
standard deviations (2 SD = 8.6) above the mean sum scores
(mean = 18.0) of the AES-S-Apathy in healthy controls from the TOP
study (previously reported in Faerden et al., 2009). Eighteen patients
were included in the PA group, and 52 patients in the NPA group.
The split version of the Global Assessment of Function (GAF) scale
(Pedersen et al., 2007), the Positive and Negative Syndrome Scale
(PANSS) (Kay et al., 1987) and the Calgary Depression Scale for Schizo-
phrenia (CDSS) (Addington et al., 1996) were administered. Dose of
current antipsychotic medication at time of MRI was converted to
Deﬁned Daily Dose (DDD) (WHO Collaborating Centre for Drug
Statistics Methodology, 2014). Age of onset was deﬁned as age when
ﬁrst experiencing positive psychotic symptoms. Duration of illness
(DOI) at the time of MRI scan was calculated in years from age of
onset to age of MRI scan. Duration of untreated psychosis (DUP) was
estimated as number of weeks with positive psychotic symptoms
scoring above 4 on the PANSS without adequate treatment.
2.3. MRI acquisition
All participants underwent MRI at baseline in a 1.5 T Siemens
Magnetom Sonata (Siemens Medical Solutions, Erlangen, Germany)
equipped with a standard head coil. After a conventional 3-plane
localizer, two sagittal T1-weighted magnetization prepared rapid
gradient echo (MPRAGE) volumes were acquired with the Siemens
tﬂ3d1_ns pulse sequence (TE = 3.93 ms, TR = 2730 ms, TI =
1000 ms, ﬂip angle = 7°; FOV = 24 cm, voxel size =
1.33 × 0.94× 1mm3, number of partitions=160) and subsequently av-
eraged together, after rigid-body registration, to increase the signal-to-
noise ratio. There was no scanner upgrade or change of instrument dur-
ing the study period. Median time from clinical interviews to MR scan-
ning was 122 days (range 21–1040 days).
2.4. MRI post-processing
MRI scanswere processed using FreeSurfer 4.5.0 software. The post-
processing involves surface reconstruction (Dale et al., 1999; Fischl
et al., 1999) to obtain measures of cortical thickness at approximately
160,000 vertices across the cortical surface (Fischl et al., 2002). The
cortical surface is further divided into 32 parcellations in each
hemisphere according to an anatomical atlas (Desikan et al., 2006). As
part of the post-processing, volumes of 34 subcortical structures are
automatically estimated (Fischl et al., 2002). For the present study we
applied cortical thickness maps smoothed with a full width at half
maximum Gaussian kernel of 30 mm. For the hypothesis driven
analyses on cortical thickness of OFC and ACC, we used left and right
mean cortical thickness of OFC (combining lateral and medial OFC)
and ACC (combining rostral and caudal ACC) (Fig. 1). For subcortical
Table 1
Demographic and clinical data for ﬁrst-episode psychosis patients with persistent apathy
(PA) and without persistent apathy (NPA) at baseline and 12 months follow-up.
Variable mean (SD), unless
otherwise stated
PA N= 18 NPA N= 52 T/U/χ2 p
Demographic
Age at MRI, years 28.1 (7.9) 27.6 (7.3) 0.234 0.816
Gender (N=male (%)) 14 (77.8) 24 (46.2) 5.4 0.02
Clinical baseline
Diagnosisa
Schizophrenia spectrum, n 17 29
Bipolar spectrum, n 0 10
Other psychosis, n 1 13
Age of onset, years 22.9 (4.5) 24.3 (7.8) −0.991 0.326
DUP, weeks (median range) 68.5 (20–1040) 31.5 (1–527) 300.00 0.024
DOI MR, years (median range) 3.0 (0–25) 2.0 (0–22) 358.50 0.136
GAF-S 35.9 (6.4) 44.4 (13.7) −3.498 0.001
GAF-F 39.0 (12.5) 47.4 (13.5) −2.399 0.022
PANSS positive 16.1 (5.3) 15.0 (5.9) 0.692 0.491
PANSS negative 20.0 (5.2) 13.3 (4.8) 4.951 0.000
PANSS total 70.9 (11.6) 58.8 (14.6) 3.201 0.002
CDSS 7.2 (4.3) 6.0 (4.2) 1.044 0.300
Antipsychotic medication at time of MRIb
DDD FGA 0.03 (0.08) 0.04 (0.17) −0.165 0.870
DDD SGA 1.18 (0.93) 0.80 (0.75) 1.752 0.084
DDD total 1.21 (0.94) 0.84 (0.76) 1.702 0.093
Clinical follow-up at 12 months
GAF symptom 42.6 (11.6) 56.8 (17.7) −3.869 0.000
GAF function 42.8 (9.8) 57.9 (16.6) −4.616 0.000
PANSS positive 15.0 (4.5) 11.6 (5.4) 2.416 0.018
PANSS negative 18.4 (3.2) 12.0 (4.6) 5.488 0.000
PANSS total 66.4 (9.5) 49.0 (13.6) 5.014 0.000
CDSS 5.6 (3.9) 4.2 (4.0) 1.303 0.197
Group differences in demographic and clinical data were tested using Student's t-test for
continuous normally distributed variables, Mann–Whitney U-test for non normally
distributed variables (DUP and DOI), and chi-square statistics for categorical data
(gender).
PA: persistent apathy, NPA: no persistent apathy, MRI:magnetic resonance imaging, DUP:
duration of untreated psychosis, DOI: duration of illness, GAF: global assessment of
function, PANSS: Positive and Negative Syndrome Scale, CDSS: Calgary Depression Scale,
DDD: deﬁned daily dose, FGA: ﬁrst-generation antipsychotics, SGA: second-generation
antipsychotics.
a Schizophrenia spectrum: schizophrenia, schizophreniform disorder, schizoaffective
disorder. Bipolar spectrum: bipolar disorder type I, bipolar disorder type II, bipolar
disorder not otherwise speciﬁed. Other psychoses: major depressive disorder with
psychotic features, delusional disorder, brief psychotic disorder, psychosis not otherwise
speciﬁed.
b 54 patients were on antipsychotic medication. Data on dose and type of medication
were missing on one subject. Forty-eight patients used only SGA, 1 patient used only FGA
and 5 patients used both types.
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were therefore combined.
2.5. Statistical analysis
Statistical analyseswere performed using SPSS version 18 (SPSS Inc.,
2009), except for the explorative cortical thickness analyses where
MATLAB version 7.9.0 (MATLAB and Statistics Toolbox Release, 2012)
was used. Bonferroni–Holm correctionwas applied to control for multi-
ple comparisons in all region-of-interest analyses (including follow-up
analyses) of brain structure differences between PA and NPA patients.
Explorative cortical thickness analyses were corrected using a 5% false
discovery rate (FDR).
2.5.1. Demographic and clinical data
Group differences in demographic and clinical data were tested
using Student's t-test for continuous normally distributed variables,
Mann–Whitney U-test for variables with a non-normal distribution
(DOI and DUP) and chi-square statistics for categorical data.
2.5.2. Hypothesis driven analyses
Linear regression models were performed with each region of
interest (cortical thickness of left and right OFC and ACC, volumes of
putamen, pallidum, caudate, accumbens, and thalamus) as dependent
variables. Age, gender, and group (PA or NPA) were independent
variables. In the subcortical volume analyses, intracranial volume
(ICV) was used to control for inter-individual skull differences.
2.5.3. Explorative analysis
2.5.3.1. Cortical thickness. We performed a surface-based analysis by
ﬁtting a general linear model at each vertex with cortical thickness as
dependent variable, and age, gender, and group (PA or NPA) as
independent variables.
2.5.3.2. Subcortical volumes. Linear regression models, as described
under Section 2.5.2, were used to explore group differences in structure
volumes not included under the a priori hypothesis (volumes of ventri-
cles, hippocampus, amygdala, and cerebellum).
2.5.4. Effect of clinical variables
Signiﬁcant results were controlled for possible confounding
variables such as dose of antipsychotics, severity of depressive
symptoms (CDSS score), and positive psychotic symptoms (PANSS
positive subscale, at baseline and follow-up) by entering them as
separate independent variables in linear regression models.
2.5.5. Analyses within schizophrenia spectrum
To test for diagnostic speciﬁcity of signiﬁcant group differences,
analyses were repeated for patients with schizophrenia spectrum
disorders (schizophrenia N = 37, schizophreniform disorder N = 2,
and schizoaffective disorder N= 7) only.
2.5.6. Post hoc comparisons against healthy controls
Post hoc comparisons against a healthy control group (see Supple-
mentary data for details) were performed in regions where signiﬁcant
differences between PA and NPA were found. Analysis of covariance
(ANCOVAs) was used, controlling for age and gender (and ICV for
subcortical volumes).
3. Results
3.1. Demographic and clinical data
Compared to NPA patients, PA patients were more often men, had
longer DUP, worse psychosocial functioning (GAF-S and GAF-F), highertotal PANSS scores, and more negative symptoms at both baseline and
follow-up (Table 1). At follow-up, the PA group also scored higher on
the PANSS positive subscale. There were no differences in medication
dose or depression score (CDSS).
3.2. Hypothesis-driven analysis
The PA group had signiﬁcantly thinner left OFC and left ACC (Fig. 2).
There were trend level thinning of right ACC (Fig. 2) and trend level
larger caudate volume (Table 2). One outlier case was removed in the
ACC analyses, as it affected the linear regression model notably (see
Supplementary data).
3.3. Explorative analyses
FDR-corrected vertex-wise comparisons of cortical thickness in PA
versus NPA did not yield any signiﬁcant results. For completeness,
trend ﬁndings at uncorrected p b 0.01 at each vertex were also investi-
gated. Cortical thinning was observed mainly in the left OFC, and in
additional scattered regions (Fig. S1). There were no signiﬁcant group
Fig. 2. Cortical thickness in left (LH) and right (RH) orbitofrontal (OFC) and anterior
cingulate cortex (ACC) in psychosis patients with persistent apathy (PA) and without
persistent apathy (NPA). Gray lines indicate unadjusted group means. P-values displayed
are derived from linear regression models comparing cortical thickness adjusted for age
and gender of each region of interest between PA and NPA patients. Signiﬁcant results
after applying Bonferroni–Holm correction are marked by an asterisk.
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volumes (Table S2).
3.4. Clinical variables
DDD of antipsychotic medication was associated with cortical
thinning in the left OFC (B = −0.044, p = 0.012). When DDD
was included in the model, the difference between PA and NPA
patients was reduced, however it remained signiﬁcant (B =−0.080,
p = 0.015). Positive symptoms at baseline correlated with cortical
thinning of left ACC (B = −0.010, p = 0.009). Adjusting for positive
symptoms did not affect the difference between PA and NPA patients
in this region (B =−0.122, p = 0.015). Controlling for depression or
positive symptoms at follow-up did not alter the results.
3.5. Schizophrenia spectrum
Follow-up analysis within schizophrenia spectrum (N = 46)
conﬁrmed thinner cortices in the PA group (N = 17) compared
to the NPA group (N = 29) in left OFC (B = −0.089, t = −2.242,
p = 0.030) and left ACC (B = −0.124, t = −2.016, p = 0.050). The
results were only trend level signiﬁcant after Bonferroni–Holm
correction.
3.6. Post hoc comparisons against healthy controls
PA patients showed reduced cortical thickness in left OFC
(p b 0.001) and left ACC (p = 0.007) compared to healthy controls.
NPA patients did not differ from healthy controls (Table S3).Table 2
Volumes (ml) of basal ganglia and thalamus in ﬁrst-episode psychosis patients with
persistent apathy (PA) and without persistent apathy (NPA).
Predicted mean volume (SE) t p
PA NPA
Thalamus 13.833 (0.226) 14.018 (0.128) −0.706 0.483
Putamen 12.472 (0.241) 12.227 (0.136) 0.876 0.384
Pallidum 3.812 (0.084) 3.782 (0.048) 0.301 0.764
Caudate 8.355 (0.188) 7.837 (0.107) 2.374 0.021
Accumbens 1.412 (0.042) 1.393 (0.024) 0.407 0.685
Dependent variables: subcortical structure volumes for hypothesized regions of interest.
Independent variables: age, gender, and intracranial volume. After applying Bonferroni–
Holm none of the results remained signiﬁcant. Predicted means (ml) are covaried for
age = 27.76 and intracranial volume = 1571.6 ml.4. Discussion
The main ﬁnding was that FEP patients with PA show cortical
thinning in left hemisphere OFC and ACC compared to FEP patients
without PA. Trend level cortical thinning in right ACC and increased
caudate volume in PA patients were also found. Alterations in left OFC
and ACC were selective to the PA group when both groups were
compared to healthy controls. To our knowledge this is the ﬁrst study
to investigate how apathy is related to cortical thickness and subcortical
volumes in FEP patients.
Previously, we have shown that PA patients differed from NPA
patients in global functioning (Faerden et al., 2010). Brain structural
abnormalities restricted to the PA group suggest that PA is a subgroup
of patients with distinct neurobiological underpinnings. Thinner frontal
cortex is a consistent ﬁnding in unselected schizophrenia samples
(Kuperberg et al., 2003; Nesvag et al., 2008; Rimol et al., 2010; Schultz
et al., 2010). Our results are in line with previously reported smaller
volumes of OFC in schizophrenia patients with persistent negative
symptoms (Benoit et al., 2012), and reduced regional blood ﬂow in
OFC in patients with deﬁcit schizophrenia (Kanahara et al., 2013).
Although larger OFC volumes with severity of negative symptoms in
schizophrenia patients have been reported (Lacerda et al., 2007), most
studies ﬁnd negative correlations between negative symptom severity
and OFC size (Baare et al., 1999; Gur et al., 2000).
The larger caudate volumes found in PA patients did not survive
adjustment for multiple comparisons. The few studies of subcortical
volumes in patients with persistent negative symptoms have mainly
been negative (Buchanan et al., 1993; Galderisi et al., 2008; Fischer
et al., 2012; Voineskos et al., 2013). Trend-level larger caudate volumes
in deﬁcit schizophrenia have been reported (Buchanan et al., 1993). We
did not replicate previously reported putamen volume reduction
(Cascella et al., 2010).
Interestingly, the cortical thinning in OFC and ACC in PA patients is
in agreement with ﬁndings in neurologic disorders where apathy is a
common feature. Gray matter reduction in the OFC and ACC has been
associated with apathy in patients with Alzheimer's disease (Apostolova
et al., 2007; Bruen et al., 2008; Guimaraes et al., 2008; Tunnard et al.,
2011; Stanton et al., 2013). In patients with amyotrophic lateral
sclerosis, severity of apathy was correlated with atrophy in OFC and
dorsolateral prefrontal cortex (Tsujimoto et al., 2011). Although
differences in methods used complicate direct comparisons, it has
been widely acknowledged that apathy is a common feature in a
range of different disorders (van Reekum et al., 2005; Foussias et al.,
2014). Putative neural associations of reward processing in OFC, ACC
and basal ganglia have been addressed in two recent reviews on
motivational deﬁcits in schizophrenia patients (Strauss et al., 2013;
Kring and Barch, 2014). Our results support the importance of these
structures in motivational deﬁcits in patients with psychosis.
The PA patients represent a subgroup of psychosis patients with a
more severe illness as reported in Faerden et al. (2010, 2013), showing
worse psychosocial functioning already at time of inclusion. At 1-year
follow-up, but not at baseline, they had higher PANSS positive score
than theNPA patients. This complicates the interpretation as towhether
the observed group differences are effects of illness severity, or medica-
tion, or are speciﬁcally related to apathy. Positive symptoms did not
affect the cortical thickness differences in left OFC or ACC between PA
and NPA patients. We found an association between antipsychotics
and cortical thickness in the left OFC, which partly explained the differ-
ence observed between PA and NPA patients. However, a signiﬁcant
group difference remained after controlling for antipsychotic medica-
tion, and there was no effect of current dose of antipsychotics in the
left ACC. Severity of illness, psychosocial functioning, and medication
are inter-related and can effect both apathy and brain structure.
Nevertheless, evidence towards involvement of OFC and ACC in aspects
of motivation (Strauss et al., 2013; Kring and Barch, 2014), taken
together with previously reported associations between these regions
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observed in our study are indeed associated with apathy.
Strengths of the present study include thorough clinical characteri-
zation of a representative FEP patient sample and a large number of
cortical and subcortical structures using validated automated methods.
Apathy was assessed both at time of inclusion and after a year, which
allows for predicting persistent apathy over theﬁrst year after inclusion.
The AES-scale offers a more speciﬁc assessment of the apathy
dimension of negative symptoms than more general symptom scales,
such as PANSS (Faerden et al., 2008).
Some limitations apply to our ﬁndings. First, the sample size,
although hitherto one of the largest, could limit the capacity to detect
smaller group differences. Second, correcting for multiple comparisons
increases the risk of running type II errors. Therefore we have also
presented nominal signiﬁcant results from hypothesized regions that
did not survive adjustment for multiple tests, such as right ACC and
caudate. When a p b 0.01 at each vertex was applied, exploratory
analyses on cortical thickness across the entire cortical surface showed
only a few additional scattered areas of thickness reduction in PA
patients (Fig. S1). Third, some subjects had a delay from time of clinical
assessments to MR scanning. This should have little inﬂuence on the
main analyses as apathy has been measured as a stable feature over
two time points. Fourth, although the AES is speciﬁcally designed to
evaluate motivational deﬁcits, and has been shown to be correlated
with a social amotivation factor of negative symptoms in PANSS
(Liemburg et al., 2015) we cannot strictly exclude that the observed
group differences are not also related to other negative symptoms
such as diminished expression.
In the present study we ﬁnd brain structure differences between PA
and NPA FEP patients. This indicates that PA patients may constitute
a subgroup of psychosis patients with a distinct neuropathology.
The observed cortical thinning in PA patients was seen in regions
hypothesized to be involved in motivation and goal directed behavior
and may be neurobiological markers of apathy in psychosis patients.
Our study contributes to the important research on neuropathology of
subdomains of negative symptoms. The OFC and ACC are important
regions of interest for future studies on the neurobiology of apathy in
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